Oncologists optimistic about chemotherapy for NSCLC

    loading  Checking for direct PDF access through Ovid

Abstract

Surgery remains the primary therapy for patients with operable non-small-cell lung cancer (NSCLC). However, the introduction of new drug classes in recent years has brought about a change in the role of chemotherapy for the treatment of NSCLC. Initially, drug treatment was primarily seen as palliative, but it is now considered to be potentially curative. Chemotherapy has a role in the adjuvant and postsurgical settings, and can be valuable in all stages of NSCLC, even in non-operable disease, according to an expert panel discussion between oncologists at the 8th International Congress on Anti-Cancer Treatment [Paris, France; February 1998].

Related Topics

    loading  Loading Related Articles